We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$424M
AUM Growth
+$63.8M
Cap. Flow
+$75.3M
Cap. Flow %
17.76%
Top 10 Hldgs %
48.45%
Holding
91
New
14
Increased
28
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$21.9M
2
ERAS icon
Erasca
ERAS
+$16.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.9M
4
URGN icon
UroGen Pharma
URGN
+$8.44M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$7.74M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$7.96M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.89M
3
SLDB icon
Solid Biosciences
SLDB
+$7.63M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.98M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$5.83M

Sector Composition

Rank Sector Weight
1 Healthcare 95.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVGN icon
51
Evogene
EVGN
$5.99M
$2M 0.47%
307,974
-576
-0.2% -$4.02K
STOK icon
52
Stoke Therapeutics
STOK
$1.83B
$1.91M 0.45%
+141,518
New +$1.91M
MGNX icon
53
MacroGenics
MGNX
$245M
$1.57M 0.37%
370,000
-108,079
-23% -$1.05M
MODD icon
54
Modular Medical
MODD
$12.7M
$1.42M 0.34%
30,000
– –
ZURA icon
55
Zura Bio
ZURA
$526M
$1.15M 0.27%
328,504
– –
TARS icon
56
Tarsus Pharmaceuticals
TARS
$2.57B
$1.09M 0.26%
+40,000
New +$1.34M
ALXO icon
57
PUT
ALX Oncology
ALXO
$268M
$1.01M 0.24%
+167,900
New +$2.06M
VYNE icon
58
VYNE Therapeutics
VYNE
$19.1M
$921K 0.22%
9,348
+7,620
+441% +$950K
EYPT icon
59
EyePoint Inc
EYPT
$1B
$870K 0.21%
100,000
-147,968
-60% -$2.07M
ETNB
60
DELISTED
89bio
ETNB
$739K 0.17%
92,298
– –
MTEM
61
DELISTED
Molecular Templates, Inc.
MTEM
$717K 0.17%
623,838
+269,230
+76% +$399K
GUTS icon
62
Fractyl Health
GUTS
$115M
$712K 0.17%
166,666
– –
CCCC icon
63
CALL
C4 Therapeutics
CCCC
$393M
$693K 0.16%
150,000
– –
SLNO
64
DELISTED
Soleno Therapeutics
SLNO
$612K 0.14%
+15,000
New +$636K
KPTI icon
65
Karyopharm Therapeutics
KPTI
$161M
$485K 0.11%
37,231
– –
MRSN
66
CALL
DELISTED
Mersana Therapeutics
MRSN
$338K 0.08%
6,732
+6,664
+9,800% +$482K
RLMD icon
67
Relmada Therapeutics
RLMD
$549M
$298K 0.07%
99,379
– –
ALGS icon
68
Aligos Therapeutics
ALGS
$26.3M
$229K 0.05%
26,221
– –
PCVX icon
69
Vaxcyte
PCVX
$7.88B
$189K 0.04%
+2,500
New +$170K
RCKTW icon
70
Rocket Pharmaceuticals Warrant
RCKTW
$352K
$6.36K ﹤0.01%
104,828
– –
ACET icon
71
Adicet Bio
ACET
$76.7M
– –
-20,705
Closed -$779K
AMLX icon
72
CALL
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-20,000
Closed -$56.8K
AMLX icon
73
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-500,000
Closed -$1.42M
APGE icon
74
Apogee Therapeutics
APGE
$10.1B
– –
-50,000
Closed -$3.32M
CRNX icon
75
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-127,835
Closed -$5.98M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Silverarc Capital Management held 91 positions worth $424M, up 18% from $360M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $75.3M of net new capital in Q2 2024, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Perspective Therapeutics, an estimated $7.96M trimmed.

  • Silverarc Capital Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
  • Silverarc Capital Management added most to Nuvalent in Q2 2024, an estimated $21.9M increase.
  • Silverarc Capital Management's biggest Q2 2024 reduction was Perspective Therapeutics, cutting an estimated $7.96M.
  • Silverarc Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $7.89M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $424M portfolio in Q2 2024.
  • Silverarc Capital Management opened 14 new positions and closed 21 in Q2 2024.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $424M.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.